Galectin Therapeutics Inc Unit Cons of 2 shs + 1 Wt
(NASDAQ : GALTU)

( )
GALTU After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Loading GALTU News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
4.42%70.480.9%$642.57m
CELGCelgene Corporation
0.64%133.681.1%$633.67m
AMGNAmgen Inc.
1.44%173.821.1%$633.64m
ALXNAlexion Pharmaceuticals, Inc.
2.14%126.231.9%$553.94m
REGNRegeneron Pharmaceuticals, Inc.
0.86%526.532.7%$546.91m
BIIBBiogen Inc.
0.71%280.571.2%$499.28m
VRTXVertex Pharmaceuticals Incorporated
0.52%135.531.9%$281.36m
INCYIncyte Corporation
1.22%135.632.6%$274.50m
CLVSClovis Oncology, Inc.
2.64%96.7818.0%$248.18m
TSROTESARO, Inc.
5.38%149.7714.7%$231.38m
PBYIPuma Biotechnology, Inc.
7.73%86.4521.1%$188.33m
ILMNIllumina, Inc.
3.16%182.993.5%$163.69m
BLUEBluebird Bio, Inc.
-1.50%118.5019.3%$156.72m
AAgilent Technologies, Inc.
1.36%60.601.5%$134.46m
EXASExact Sciences Corporation
-0.80%34.7126.3%$127.68m

Company Profile

Galectin Therapeutics, Inc. operates as a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease and cancer. Its drug candidates are based on the method of targeting galectin proteins, which are key mediators of biologic and pathologic function and its focus is on diseases with serious, life-threatening consequences to patients and those where current treatment options are limited. The company was founded by James C. Czirr and Anatole A. Kltyosov on July 10, 2000 and is headquartered in Norcross, GA.,0038VL-E